Table 1.

Cases with FD treated with denosumab in the previous literature.

References	Number of patients	FD type	Treatment	Effect on bone pain	Bone resorption marker	Radiographic improvement	BPs prior to denosumab treatment	Adverse events	Duration of denosumab treatment
Boyce, 2012[12]	1	MAS	1 mg/kg, every 3 M	Yes	CTX	No	Yes	Hypercalcemia after discontinuation	7 M
Ganda, 2013[10]	2	PFD (2)	60 mg, every 6–9 M (case1), every 4 M (case2)	Yes	uDPD	NA	Yes	None	NA
Eller-Vainicher, 2016[7]	1	MFD	60 mg, every 3 M	Yes	CTX	Yes	Yes	None	27 M
Majoor, 2019[9]	12	PFD (7) MAS (4) MFD (1)	60 mg, every 3–6 M	Yes (10)	CTX	NA	Yes	Skin rash (1)	median 15.5 M
Meier, 2021[17]	37	PFD (21) MAS (9) MFD (7)	60 mg, every 3–6 M	Yes∗	CTX	NA	Yes (34)	Osteonecrosis of jaw (1), oral blisters (1)	median 1.6 yr
van der Bruggen, 2021[18]	8	PFD (5) MAS (2) MFD (1)	60–120 mg, every 3–6M	NA	NA	Yes	No	NA	NA
Raborn, 2021[11]	1	MFD	53–70 mg, every 1–3M	Yes	CTX	Yes	Yes	Hypercalcemia after discontinuation	3.5 yr
Meier, 2021[8]	2	PFD (2)	60 mg, every 3M	Yes	CTX	Yes	Yes	None	5.3–5.5 yr